Trials / Completed
CompletedNCT03914443
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- National Cancer Center, Japan · Other Government
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of the neoadjuvant therapy, nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced esophageal carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | 240 mg or 360 mg |
| DRUG | 5-FU | 750 or 800 mg\^2 |
| DRUG | CDDP | 70 or 80 mg/m\^2 |
| DRUG | DTX | 70 mg/m\^2 |
Timeline
- Start date
- 2019-05-07
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2019-04-16
- Last updated
- 2025-05-31
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03914443. Inclusion in this directory is not an endorsement.